Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Matthew Kaplan is an analyst at Ladenburg Thalmann. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 03/26/2025
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 11/18/2024 | EYEN | Buy Now | Eyenovia | $1.28 | — | Matthew Kaplan67% | — | Downgrade | Buy → Neutral | Get Alert |
| 10/31/2024 | UTHR | Buy Now | United Therapeutics | $317.50 | 8.35% | Matthew Kaplan67% | $319 → $344 | Maintains | Buy | Get Alert |
| 06/14/2024 | URGN | Buy Now | UroGen Pharma | $11.40 | 369.3% | Matthew Kaplan67% | $48 → $53.5 | Maintains | Buy | Get Alert |
| 05/02/2024 | TGTX | Buy Now | TG Therapeutics | $43.00 | -6.98% | Matthew Kaplan67% | $39 → $40 | Maintains | Buy | Get Alert |
| 04/18/2024 | TGTX | Buy Now | TG Therapeutics | $43.00 | -9.3% | Matthew Kaplan67% | → $39 | Reiterates | Buy → Buy | Get Alert |
| 12/21/2023 | LQDA | Buy Now | Liquidia | $15.60 | 92.31% | Matthew Kaplan67% | $15 → $30 | Maintains | Buy | Get Alert |
| 08/03/2023 | ARDX | Buy Now | Ardelyx | $5.19 | 63.78% | Matthew Kaplan67% | $7.5 → $8.5 | Maintains | Buy | Get Alert |
| 08/03/2023 | UTHR | Buy Now | United Therapeutics | $317.50 | -15.59% | Matthew Kaplan67% | $256 → $268 | Maintains | Buy | Get Alert |
| 07/31/2023 | RETA | Buy Now | Reata Pharmaceuticals | — | — | Matthew Kaplan67% | $122 → $172.5 | Downgrade | Buy → Neutral | Get Alert |
| 06/29/2023 | RETA | Buy Now | Reata Pharmaceuticals | — | — | Matthew Kaplan67% | $104 → $122 | Maintains | Buy | Get Alert |
| 05/04/2023 | UTHR | Buy Now | United Therapeutics | $317.50 | -19.37% | Matthew Kaplan67% | $285 → $256 | Maintains | Buy | Get Alert |
| 05/02/2023 | AVDL | Buy Now | Avadel Pharmaceuticals | $8.20 | 95.12% | Matthew Kaplan67% | $14.5 → $16 | Maintains | Buy | Get Alert |
| 05/02/2023 | TGTX | Buy Now | TG Therapeutics | $43.00 | -12.79% | Matthew Kaplan67% | $26 → $37.5 | Maintains | Buy | Get Alert |
| 03/21/2023 | ATNX | Buy Now | Athenex | — | — | Matthew Kaplan67% | — | Downgrade | Buy → Neutral | Get Alert |
| 02/08/2023 | KPRX | Buy Now | Kiora Pharmaceuticals | $3.05 | 3801.64% | Matthew Kaplan67% | → $1071 | Reiterates | → Buy | Get Alert |
| 08/25/2022 | KPRX | Buy Now | Kiora Pharmaceuticals | $3.05 | 113.11% | Matthew Kaplan67% | → $2340 | Initiates | → Buy | Get Alert |
| 07/22/2022 | LQDA | Buy Now | Liquidia | $15.60 | -3.85% | Matthew Kaplan67% | → $15 | Initiates | → Buy | Get Alert |
| 06/29/2022 | XAIR | Buy Now | Beyond Air | $0.30 | 7564.11% | Matthew Kaplan67% | $17 → $23 | Maintains | Buy | Get Alert |
| 04/14/2022 | ATRS | Buy Now | Antares Pharma | — | — | Matthew Kaplan67% | — | Downgrade | Buy → Neutral | Get Alert |
| 03/21/2022 | ALNA | Buy Now | Allena Pharmaceuticals | — | — | Matthew Kaplan67% | — | Downgrade | Buy → Neutral | Get Alert |
| 02/25/2022 | UTHR | Buy Now | United Therapeutics | $317.50 | -36.06% | Matthew Kaplan67% | $231 → $203 | Maintains | Buy | Get Alert |
| 12/01/2021 | ARDX | Buy Now | Ardelyx | $5.19 | 15.61% | Matthew Kaplan67% | → $6 | Upgrade | Neutral → Buy | Get Alert |
| 11/22/2021 | RPHM | Buy Now | Reneo Pharmaceuticals | — | — | Matthew Kaplan67% | → $450 | Initiates | → Buy | Get Alert |
| 10/14/2021 | ARDX | Buy Now | Ardelyx | $5.19 | — | Matthew Kaplan67% | — | Downgrade | Buy → Neutral | Get Alert |
| 01/06/2021 | MLND | Buy Now | Millendo Therapeutics | — | — | Matthew Kaplan67% | — | Downgrade | Buy → Neutral | Get Alert |
| 12/10/2020 | LPCN | Buy Now | Lipocine | $3.45 | -13.04% | Matthew Kaplan67% | → $51 | Upgrade | Neutral → Buy | Get Alert |
| 10/14/2020 | COGT | Buy Now | Cogent Biosciences | $7.02 | -43.02% | Matthew Kaplan67% | → $16 | Initiates | → Buy | Get Alert |
| 01/22/2020 | TARA | Buy Now | Protara Therapeutics | $4.31 | 944.08% | Matthew Kaplan67% | → $45 | Initiates | → Buy | Get Alert |
| 08/01/2019 | UTHR | Buy Now | United Therapeutics | $317.50 | -66.61% | Matthew Kaplan67% | $103 → $106 | Upgrade | Neutral → Buy | Get Alert |
| 10/25/2018 | ATNX | Buy Now | Athenex | — | — | Matthew Kaplan67% | → $540 | Initiates | → Buy | Get Alert |
| 08/02/2018 | ALNA | Buy Now | Allena Pharmaceuticals | — | — | Matthew Kaplan67% | → $23 | Initiates | → Buy | Get Alert |
| 01/12/2018 | ARDM | Buy Now | Aradigm | — | — | Matthew Kaplan67% | — | Downgrade | Buy → Neutral | Get Alert |
| 04/13/2017 | RETA | Buy Now | Reata Pharmaceuticals | — | — | Matthew Kaplan67% | → $55 | Initiates | → Buy | Get Alert |
| 02/16/2017 | ALBO | Buy Now | Albireo Pharma | — | — | Matthew Kaplan67% | → $40 | Initiates | → Buy | Get Alert |
| 10/28/2016 | UTHR | Buy Now | United Therapeutics | $317.50 | — | Matthew Kaplan67% | — | Upgrade | Neutral → Buy | Get Alert |
| 04/29/2016 | UTHR | Buy Now | United Therapeutics | $317.50 | — | Matthew Kaplan67% | — | Downgrade | Buy → Neutral | Get Alert |
| 03/31/2016 | ARDX | Buy Now | Ardelyx | $5.19 | 304.62% | Matthew Kaplan67% | → $21 | Initiates | → Buy | Get Alert |
| 12/23/2013 | UTHR | Buy Now | United Therapeutics | $317.50 | -56.54% | Matthew Kaplan67% | → $138 | Upgrade | Neutral → Buy | Get Alert |
| 04/30/2012 | UTHR | Buy Now | United Therapeutics | $317.50 | -81.73% | Matthew Kaplan67% | $61 → $58 | Maintains | Buy | Get Alert |
